Broad Agency Announcement for the Defense Health Agency

Joint Warfighter Medical Research Program

Military Medical Research and Development Award

Funding Opportunity Number: HT942526JWMRPMMRDA

Preapplication/Preproposal Due: August 18, 2026

Application/Proposal Due: November 16, 2026

This broad agency announcement must be read in conjunction with the General Submission Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application/proposal submission.** User registration for each of these websites can take several weeks or longer. Each applicant/offeror must ensure their registrations are active and up to date prior to application/proposal preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application/proposal materials.** It is the responsibility of the applicant/offeror to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to preapplication/preproposal or intramural full application/proposal submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is **intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries.** The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. **Projects must be relevant to at least one of the FY26 JWMRP focus areas**.

Distinctive Features:

To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.

An **MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO)** is available to specifically support clinical research/observational studies, all phases of clinical trials /interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/ proposal materials.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $8.8M to fund approximately two MMRDA applications/proposals with total cost caps of $1.4M per award for the MMRDA, and approximately two MMRDA-CRCTO applications/proposals with total cost caps of $3.0M per award for the MMRDA-CRCTO. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Preapplication/Preproposal Submission Deadline:** 5:00 p.m. Eastern Time (ET), August 18, 2026
- **Invitation to Submit an Application/Proposal:** September 3, 2026
- **Application/Proposal Submission Deadline:** 11:59 p.m. ET, November 16, 2026
- **End of Application/Proposal Verification Period:** 5:00 p.m. ET, November 23, 2026
- **Peer Review:** February 2026
- **Programmatic Review:** April/May 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526JWMRPMMRDA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants/Offerors

2.1.1. Organization

Extramural and intramural DOW organizations are eligible to apply*, **including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

Extramural Organization: A foreign or domestic non-DOW organization. Examples of extramural organizations include, but are not limited to, academic institutions, biotechnology companies, foundations, federal government organizations other than the DOW (i.e., intragovernmental organizations) and research institutes.

Intramural DOW Organization: A subset of intragovernmental organizations; refers specifically to DOW organizations, including DOW laboratories, DOW military treatment facilities, and/or DOW activities embedded within a civilian medical center.

In accordance with Department of Defense Instruction (DoDI) 5000.77 and FAR 35.017, Federally Funded Research and Development Centers (FFRDCs) are not eligible to directly receive awards under this Broad Agency Announcement (BAA). However, teaming arrangements between FFRDCs and eligible organizations are allowed as long as they are permitted under the sponsoring agreement between the federal government and the specific FFRDC.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application/proposal, regardless of ethnicity, nationality or citizenship status.

To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.

There are no limitations on the number of applications/proposals for which an investigator may be named as a PI.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement for contracts or assistance agreements, but may exist if Research Other Transaction (OT) or Prototype OT is the selected funding instrument. Cost-sharing requirements for OTs are stated in 10 USC 4021 for Research OTs and 10 USC 4022 for Prototype OTs.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the General Submission Instructions, Appendix 1, for additional awardee qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications/proposals to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the JWMRP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the JWMRP in 2012 to augment and accelerate high-priority DOW and service medical requirements to continue prior-year initiatives that are close to achieving their objectives and yield a benefit to military medicine. The ultimate goal of the program is to expedite the delivery of highly impactful medical solutions to Service Members and Military Health System beneficiaries; in order to ensure the highest degree of military relevance, advanced product development communities are critical partners in executing the JWMRP. Appropriations for the JWMRP from FY12 through FY25 totaled $615 million (M). The FY26 appropriation is $10M.

3.1. Award History

The JWMRP first offered awards in FY12. Since then, a total of 194 individual projects have received funding.

3.2. Intent of the Military Medical Research and Development Award

The MMRDA mechanism is intended to fund the logical continuation of previously DOW-funded research or development efforts that are relevant to the FY26 JWMRP focus areas and have the highest potential to augment and accelerate military-relevant medical product development and health care solutions for Service Members, with the potential for benefit among Veterans, military Family beneficiaries and the American public.

To be eligible for JWMRP funding, applicants/offerors must have previously received DOW core or DOW Congressional Special Interest funding (including DOW Small Business Innovation Research [SBIR]/Small Business Technology Transfer [STTR] awards) consistent with the research area being proposed for continuation under this MMRDA. Research proposed under the FY26 JWMRP MMRDA must demonstrate a logical continuation of previous DOW-funded research and development efforts with relevance to at least one of the FY26 JWMRP focus areas. If the previous DOW-funded award is no longer active, the period of performance must have been completed no more than two years prior to the preapplication/preproposal submission deadline. The funding shall be awarded at DOW discretion following a review of medical research and development gaps as well as the unfinanced medical requirements of the services. **This FY26 JWMRP BAA does not support new project concepts or basic research.**

The **MMRDA** supports research projects spanning late-stage preclinical studies, late-stage technology development efforts, technology demonstration and translational research.

The **MMRDA-CRCTO** supports clinical research/observational studies, all phases of clinical trials/interventional studies and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Note: Applicants/offerors selecting this option are required to submit additional relevant application/proposal materials, as described in Section 4.3, Full Application/Proposal Components.

3.2.1. Focus Areas for the MMRDA

The JWMRP Programmatic Panel identified the following focus areas as the highest priorities for FY26 JWMRP funding to meet critical research and development gaps and service medical requirements. **To meet the intent of the funding opportunity, applications/proposals to the FY26 JWMRP must address at least one of the focus areas listed below.**

- Non-vaccine approaches to prevent endemic diarrheal disease and broad-spectrum antivirals to prevent and/or treat emerging or endemic infectious diseases, excluding malaria
- Solutions to mitigate hemorrhage and/or support trauma resuscitation, including but not limited to blood, biologics and therapeutics
- Solutions to prevent and/or treat injuries due to temperature extremes (e.g., heat exhaustion, heat stroke, hypothermia and frostbite)
- Solutions to support forward treatment of musculoskeletal injuries (MSKI) and reduce impact of MSKI on operational effectiveness
- Medical countermeasures to radiation exposure, including pre-exposure prophylaxis, biodosimetry (inclusive of rapid screening and diagnostic tools), and post-exposure treatments (excluding cytokines)

3.2.2. Key Elements for the MMRDA

The following are important aspects of the FY26 JWMRP MMRDA:

Impact: The overall impact of the proposed research is a key component of this award mechanism. The application must clearly exhibit the project's potential impact on improving the delivery of military-relevant health care solutions. High-impact research is expected to lead to the development, translation, and/or implementation of medical solutions for military application.

Relevance to Military Health: Relevance to the care of military Service Members is a key feature of this award. The proposed research should exhibit potential to augment and/or accelerate the development of materiel/knowledge products or outcomes with direct relevance to military medicine.

Technology/Knowledge Readiness: Tangible products under development must be at or above Technology Readiness Level (TRL) 5 (e.g., proof-of-concept and prototype development must be well-established in appropriate preclinical models, if applicable; non-GLP in vivo toxicity and efficacy of lead compound complete; or preliminary FDA [or equivalent] discussions complete). Studies proposing knowledge products must be at or above Knowledge Readiness Level (KRL) 5 (see Appendix 3) (e.g., ready to test *a priori* hypotheses using rigorous scientific design, or clinical validation of a diagnostic tool). All projects should exhibit strong potential for eventual transition to advanced development and/or implementation into military medical settings in the near future.

3.2.3. Other Important Considerations for the MMRDA

This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2)(i) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for *applied research,* as well as that part of development not related to developing a specific system or hardware procurement.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Animal research is allowed within this funding opportunity.

Clinical research (including clinical trials) is allowed within this funding opportunity.

A clinical trial is defined in the Code of Federal Regulations, Title 32, Part 219.102 (32 CFR 219.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. An ***intervention*** includes both physical procedures by which information or biospecimens are gathered, and manipulations of the subject or the subject's environment that are performed for research purposes.

Studies that do not seek to measure safety, effectiveness and/or efficacy outcome(s) of an intervention are not considered clinical trials.

For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens and/or interaction with human subjects. Clinical research is observational in nature and includes:

(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does ***not*** seek to assess the safety, effectiveness and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease; (b) diagnostic or detection studies (e.g., biomarker or imaging); (c) health disparity studies; and (d) development of new technologies.

(2) Epidemiologic and behavioral studies that do ***not*** seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.

(3) Outcomes research and health services research that do not fit under the definition of clinical trial.

Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications/proposals from investigators within the DOW and applications/proposals involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application/proposal must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under this BAA will be assistance agreements, contracts, or OTs. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The DHACA will also consider the use of OTs as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.

An **assistance agreement** can take the form of a **grant** or **cooperative agreement**. The level of involvement on the part of CDMRP during the project's period of performance is the key factor in determining whether to award a grant or cooperative agreement. If "no substantial involvement" on the part of CDMRP is anticipated, a grant will be made (31 USC 6304). Conversely, if "substantial involvement" on the part of CDMRP is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate or participate in project activities.

A **contract** is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government (31 USC 6303).

An **"OT"** is utilized for certain awards when the government determines execution of the project requires flexibility (10 USC 4021 and 10 USC 4022). Such flexibility may allow for incorporation of dynamic commercial industry standards and best practices or adjustment of project scope to evolving requirements of government use cases.

The award type, along with the start date, will be determined during the negotiation process.

3.4. Funding Details

Period of Performance**:** The maximum period of performance is **3** years.

Cost Cap**:** The application/proposal's total costs budgeted for the entire period of performance should not exceed **$1.4M for the MMRDA** or **$3.0M for the MMRDA-CRCTO**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant/offeror may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

Must be requested for:

- Travel Costs for the PI to present project information or disseminate project results at one DOW-sponsored meeting (e.g., Military Health System Research Symposium) in Year 2 or 3 of the period of performance.

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the JWMRP MMRDA or MMRDA-CRCTO.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Tuition.

4. Application/Proposal Contents and Format

4.1. Application/Proposal Overview

Application/proposal submission is a two-step process requiring both a ***preapplication/ preproposal*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application/proposal*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application/proposal will differ.

Intramural DOW organizations submitting a full application/proposal should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application/proposal must follow instructions for submission through Grants.gov.

4.2. Preapplication/Preproposal Components

Preapplication/preproposal submissions must include the following components.

- **Preapplication/preproposal Template (six-page limit)**: Download from eBRAP and provide responses to the questions in the **FY26 JWMRP Preapplication/preproposal Template**. Refer to Appendix 3, Technology/Knowledge Readiness Level Definitions. No figures, charts, graphs, or other additional material will be accepted during the preapplication/preproposal process.

4.3. Full Application/Proposal Components

Applicants/offerors must receive an invitation to submit a full application/proposal. Uninvited full application/proposal submissions will be rejected.

Each application/proposal submission must include the completed full application/proposal package for this BAA. See Appendix 1 for a checklist of the full application/proposal components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*: Refer to the General Submission Instructions, Section IV.B.(a), for detailed information.

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during preapplication/preproposal submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application/proposal components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Submission Instructions, Appendix 2.

- **Attachment 1: Project Narrative (20-page limit): Upload as "ProjectNarrative.pdf".** The Project Narrative is the main body of the application/proposal. The page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application/proposal.

Describe the proposed project in detail using the outline below.

- **Background:**
  - Describe the previously funded research or materiel/knowledge product development effort identified in the notification of invitation, including a description of the accomplishments and outcomes from that award. Explain how this proposed effort is a logical continuation of the previous research or materiel/knowledge product development effort.
  - Explain how the research has the potential to augment and/or accelerate medical product development in at least one of the FY26 JWMRP Focus Areas.
  - Present the scientific rationale to support the feasibility of the proposed research or materiel/knowledge product development effort, including relevant literature citations, preliminary data, and/or preclinical data that led to the development of the proposed research. The applicant/offeror may reference published or unpublished preliminary data; however, any unpublished preliminary data should originate from the laboratory of the PI or member(s) of the collaborating team.
  - Provide sufficient evidence to support moving into the proposed stage of research.
  - As applicable to the proposed research, provide a summary of relevant studies, clinical studies, or clinical trials, and distinguish how the proposed study differs from other relevant or recently completed research or clinical trials. If applicable, include a discussion of any current clinical use of the intervention under investigation and/or details of clinical trial results for other indications.
- **Hypotheses/Objectives:** Clearly state the hypothesis (if applicable), a purpose statement and/or the objective(s) to be reached.
- **Specific Aims:** Concisely explain the project's specific aims. These aims should agree with the primary aims and associated tasks described in the Statement of Work (SOW). If this application/proposal is part of a larger study, present only tasks that this award would fund. Avoid interdependency of specific aims when possible (i.e., dependency on successful outcomes of other ongoing related research efforts).
- **Research Strategy and Feasibility:** Describe the proposed research strategy and feasibility of the approach, addressing the following:
  - Describe the study design, methods and analyses, including appropriate controls, choice of animal model (if applicable) and the endpoints/outcome measures in sufficient detail for evaluation of feasibility and effectiveness in supporting completion of the project aims.
  - Describe the availability of and access to the necessary study resources. If human-derived biological specimens will be used, describe the sourcing and/or acquisition of samples. If dataset(s) or human-derived specimens will be obtained from military Service Members, military Families and/or Veteran population(s), describe the feasibility of accessing the samples/dataset(s).
  - Explain how the study is designed to achieve reproducible and rigorous results, including (if applicable) controls, sample size estimation, power analysis, blinding, randomization and data handling
  - Applications/proposals that include research on animal models are also required to submit Attachment 8, Animal Research Plan.

- Applications/proposals that include human subjects, human biological samples (prospective or retrospective) or human data sets are also required to submit Attachment 9, Study Population Recruitment/Sample Acquisition and Safety Plan.
- Describe potential pitfalls, including interdependency of aims (i.e., dependency on successful outcomes of other ongoing related research efforts), and discuss alternative methods/approaches that may be employed to overcome them.

In addition, for applications/proposals submitted under the MMRDA-CRCTO:

- Indicate whether the proposed clinical study is observational or experimental. Include the following components, as applicable: describe the intervention, including the complete name of the investigational product, storage and handling information, source, dose, schedule, administration route and duration of the intervention. Indicate who holds the intellectual property rights to the intervention, if applicable, and how the PI has obtained access to those rights, along with access to the intervention itself, for conduct of the clinical trial.
- Outline the proposed clinical study/trial methodology and study variables in sufficient detail to demonstrate a clear course of action and justification. **For studies proposing clinical trials**, describe the type of clinical trial to be performed (e.g., treatment, prevention, diagnostic), the phase of trial and/or class of device (as appropriate), and the study model (e.g., single group, parallel, crossover).
- Identify and describe the observation/intervention and the projected outcomes. Describe how the outcomes address current clinical needs and how they compare with currently available standards of care.
- Provide a schedule (e.g., flowchart or diagram) of study observations/ interventions, evaluations, and follow-up procedures, including any data or sample collection.
- Explain how the study is designed to achieve reproducible and rigorous results, including (if applicable) controls, sample size estimation, power analysis, blinding, randomization and data handling. Provide an estimate of the recruitable population and the enrollment target. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe any measures to reduce bias.
- Describe the statistical plan and the rationale for the statistical methodology, including the sample size projections and as applicable, any subgroup analyses.
- If applicable, explain how the statistical plan compensates for the use of a subpopulation within the recruited sample population to ensure appropriate power can be achieved within the subpopulation.
- Describe data collection and handling, including rules for stopping data collection, how outliers will be defined and handled, and identification of primary endpoints/outcomes.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".** Begin each document on a new page. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures or drawings. These items should be included in the Project Narrative. Submitting material that is not requested may be viewed as an attempt to gain an unfair competitive advantage; such material will

be removed, or the application/proposal may be administratively withdrawn. ***Letters of support not requested in the broad agency announcement, such as those from members of Congress, will be removed from the application/proposal package.***

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support (two-page limit per letter is recommended): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Sex as a Biological Variable Strategy (two-page limit is recommended): Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Background and Proprietary Information: Provide a list of all background intellectual property to be used in the project or provide a statement that none will be used. All software and data first produced under this BAA are subject to a federal purpose license. Therefore, it is important to disclose/list any intellectual property (software, data, patents, etc.) that will be used in performance of the project. If applicable, all proprietary information to be provided to the government should be stated and identified; the applicant/offeror should indicate whether a waiver of the federal purpose license will be required. Additional information can be found in the 2 CFR 200.315, "Intangible Property."

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

Quad Chart: Provide a Quad Chart for the proposed project. The format for the quad chart is available on the eBRAP "Funding Opportunities & Forms" webpage.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".** The technical abstract is used by all reviewers. ***Abstracts of all funded research projects will be posted publicly.*** Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

  Background: State how the proposed research addresses at least one of the FY26 JWMRP Focus Areas. Present the scientific rationale behind the proposed work. Include the current TRL/KRL of the product or knowledge outcome (must be 5 or greater), and the estimated target TRL/KRL upon completion of the proposed research. See Appendix 3 for TRL/KRL guidance.

  Hypothesis/Objective(s): State the hypothesis and/or objective(s).

  Specific Aims: State the specific aims of the study.

  Study Design: Describe the study design, including appropriate controls. For applications/proposals that include clinical trials, state the type of clinical trial proposed (e.g., treatment, prevention, diagnostic), the phase of the trial, the class of device (as appropriate), and the study model (e.g., single group, parallel, crossover). State the proposed intervention and the primary projected outcome(s) of the clinical trial.

Impact and Military Relevance: Highlight the likely contributions of the initiative to augment and/or accelerate a materiel/knowledge product development effort. Describe the military health relevance. Briefly explain how the proposed project will have an immediate or potential long-term benefit expected to have a major impact on the health and well-being of Service Members, with the potential to benefit military Families, Veterans and/or the American public.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".** The lay abstract is used by all reviewers and addresses issues of particular interest to the affected community. ***Abstracts of all funded research projects will be posted publicly.*** Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. ***Do not duplicate the technical abstract.***

  The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine*.** Avoid overuse of scientific jargon, acronyms and abbreviations.

  - Summarize the objectives and rationale for the proposed research.
  - What population will the research help, and how will it help them?
  - What are the potential applications, benefits and risks of the anticipated outcomes?
  - What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
  - Describe how the results of the proposed study will ultimately benefit military Service Members.

- **Attachment 5: Statement of Work (six-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

  For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Impact Statement and Military Relevance Statement (two-page limit): Upload as "Impact.pdf".** The impact statement should address the points outlined below written ***in a manner that is readily understood by readers without a background in science or medicine.***

  Explain why the proposed research or materiel/knowledge product development effort is important and relevant to the role of the JWMRP in addressing high-priority DOW medical requirements and capability gaps. Additionally, describe how the effort will accelerate the development of products that will impact the Warfighter within the context of the FY26 JWMRP Focus Area(s) addressed by the application/proposal.

  Describe the potential impact on military populations. Provide information about the incidence and/or prevalence of the disease or condition in military populations (if known).

  Describe how the proposed product/knowledge will lead to the development and eventual translation of therapeutic or technological advances in the care of military

Service Members with the potential to benefit military Family beneficiaries, Veterans and the American public.

Describe how the research will result in improvement over currently available military health care standards and practices.

Describe the short-term impact. Detail the anticipated short-term outcome(s)/ product(s) (knowledge and/or materiel) of the proposed research or knowledge/ materiel product development effort, and describe how they will impact the relevant populations.

Describe how the study will augment and/or accelerate product development, as applicable.

If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

- **Attachment 7: Post-Award Transition Plan (three-page limit): Upload as "Transition.pdf".** Discuss the anticipated methods and strategies necessary to move the anticipated research outcome (e.g., knowledge, methodology, product, intervention) to the next phase of development (e.g., next-phase clinical trials, approval by a Regulatory Agency, commercialization/transition to industry, incorporation into clinical practice, and/or delivery to the civilian or military market) assuming successful completion of the award. Applicants/offerors are encouraged to work with their organization's Technology Transfer Office (or equivalent) to develop the transition plan. Applicants/offerors are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the research outcome into the next phase of development. ***The post-award transition plan should:***
  - Name the project's anticipated research outcomes including knowledge products and/or clinical products for development. A "knowledge product" is a non-materiel product that aims to transition into medical practice, training, tools or to support materiel solutions; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
  - Demonstrate how the proposed product or knowledge outcome is currently at a minimum TRL/KRL of 5 and estimate the target TRL/KRL upon completion of the proposed research.
  - Include a timeline with defined milestones for transitioning the anticipated research outcomes to the next phase of development. Include steps toward Regulatory Agency approval, if applicable. Describe the steps necessary to adapt and transition the knowledge/product/intervention from civilian application to military fielding/ adoption/use.
  - Describe current or planned collaborations and other resources (e.g., DOW partners, clinical partners, commercial partners, manufacturing partners, clinical practice guideline development committees, training providers/resources) to execute the steps toward regulatory approval. Include a discussion of the funding strategy necessary to transition the research outcome to the next level of investigation, development and/or commercialization. This may include commercial sponsorship, venture capital, federal or non-federal funding opportunities, etc. Include whether there is a commercial market for the knowledge/product/intervention or if the anticipated medical solutions are specific to a military market.

- Describe ownership rights/access to the intellectual and/or material property necessary for the development and/or commercialization of products or technologies supported with this award, as well as the government's ability to access such products or technologies in the future. Include an Intellectual and Material Property Plan for resolving intellectual and material property issues among participating organizations. If the applicant/offeror does not own the intellectual property rights, describe the steps necessary to make the product available to the target population.
- If prior federally funded SBIR/STTR data supports the proposed follow-on development effort, describe the connection between the prior SBIR/STTR and the current project and explain all active SBIR/STTR data rights.
- Include a risk analysis for cost, schedule, manufacturability and sustainability, if applicable.

- **Attachment 8: Animal Research Plan (three-page limit): Upload as "AnimalResPlan.pdf".** ***(Attachment 8 is only applicable and required for applications/proposals proposing animal studies.)*** If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application/proposal. ***Proposed studies should not rely on samples, reagents, or tools that are contingent upon completion of other ongoing efforts outside the scope of this proposal.*** Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:
  - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
  - Summarize the proposed animal procedures. Describe any planned controls.
  - Describe the planned randomization and blinding procedures and any other measures to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not occur, provide justification.
  - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 9: Study Population Recruitment/Sample Acquisition and Safety Plan (no page limit): Upload as "HumSubProc.pdf".** ***(Attachment 9 is applicable and required for all applications/proposals submitted under the MMRDA-CRCTO.)*** If the proposed study involves human subjects, human biological samples (prospective or retrospective), or human data sets the applicant/offeror is required to submit the following information, as applicable to the proposed research. ***Proposed studies should not rely on samples, reagents or tools that are contingent upon completion of other ongoing efforts outside the scope of this proposal.***

- **Enrollment Distribution:** Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity using the Public Health Service (PHS) Inclusion Enrollment Report, which is a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study. ***Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, sex, race, or ethnicity (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.***
- **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical study/trial. If limiting inclusion by age, sex, race or ethnicity, provide a strong rationale based on justification from scientific literature, preliminary data or other relevant considerations. List and describe any evaluations (e.g., laboratory procedures, history or physical examination) that are required to determine eligibility/ suitability for study participation and the diagnostic criteria for entry. Describe how the study population represents the population anticipated to benefit from the outcome/intervention.
- **Study Population/Sample Availability:** Demonstrate that the research team has access to the proposed study/sample population at each site. Describe the approximate number, pertinent demographic information and other relevant characteristics of the study population at each enrollment site. Indicate whether the actual size of available study population may be affected by ongoing clinical studies/ trials that compete for the same population. If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Submission Instructions, Appendix 4, for additional considerations.
- **Recruitment and Retention Process:** Explain methods for identification of potential study participants (e.g., medical record review, obtaining sampling lists, health care provider identification). Describe the recruitment process in detail. Address who will identify potential study participants, who will recruit them, and what methods will be used to recruit them. Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for study participants. Include a detailed description of and justification for a participant compensation plan, if applicable. Describe the strategy to retain study participants. Discuss past efforts in recruiting and retaining study participants for previous clinical studies/trials, if applicable. Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment or poor retention. Estimate the potential for participant loss to follow-up, and describe plans for handling/mitigating loss. Indicate whether the study team has considered barriers to clinical study/trial participation and, if applicable, how the team aims to mitigate or overcome these barriers.
- **Women and Minorities in the Study:** Describe the strategy for recruitment, enrollment and retention specific to women and minorities in the clinical trial appropriate to the objectives of the study, or a justification for limiting enrollment to specific groups.

- **Informed Consent Process:** Specifically describe the plan for obtaining informed consent from study participants. Include information regarding the timing and location of the consent process. If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, describe the plan to obtain assent (agreement) from those with the capacity to provide it or a justification for a waiver of assent. Appendix 6 of the General Submission Instructions contains additional considerations unique to DOW-sponsored research.
- **Risks/Benefits Assessment:**
  - **Foreseeable Risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Address any special precautions to be taken by study participants before, during and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention). If applicable, identify any potential risk to the study personnel.
  - **Risk management and emergency response:** Appropriate to the study's level of risk, describe how safety monitoring and reporting to the IRB and Regulatory Agency (if applicable) will be managed and conducted. Describe all safety measures to minimize and/or eliminate risks to study participants and study personnel or to manage unpreventable risks. Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
  - **Potential benefits:** Describe known and potential benefits to the study participants. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to study participants are reasonable in relation to the anticipated benefits to the study participants and others that may be expected to result.

- **Attachment 10: Regulatory Strategy (no page limit): If submitting multiple documents, start each document on a new page. Combine and upload as a single file named "Regulatory.pdf".** ***(Attachment 10 is applicable and required for all applications/proposals submitted under the MMRDA-CRCTO.)*** Answer the following questions and provide supporting documentation as applicable.
  - State the product/intervention name.

  For products/interventions that do not require regulation by a Regulatory Agency:

  - Provide evidence that the clinical study/trial does not require regulation by a Regulatory Agency. Submissions providing "not applicable," "none" or similar responses do not satisfy this request. No further information for this attachment is required.

  For products/interventions that require regulation by a Regulatory Agency:

  - Describe the overall regulatory strategy and product development plan that will be performed during the project's period of performance to support the planned product indication/label. Include, as appropriate, a description of the regulatory application submission strategy.
    - State whether the product is U.S. Food and Drug Administration (FDA)-approved, -licensed or -cleared and marketed in the United States. If the product is marketed in the United States, state the product label indication. State whether the proposed research involves a change to the approved label indication.

- If the product is not currently FDA-approved, -licensed or -cleared, state the planned indication/use and whether an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application was submitted. **If an IND or IDE application is required,** provide detailed plans for initiating the clinical study within the first year, including FDA IND/IDE application submission plans **within 60 days of the award.** The IND or IDE application should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and indication to be tested in the proposed clinical study/trial. If an IND/IDE has already been submitted provide the date of submission, the application number and a copy of the FDA letter acknowledging the submission. The government reserves the right to withdraw funding if this documentation has not been obtained within 60 days of the start date of the award/contract**.**
- Provide a summary of any meetings the research team has had with regulatory agencies or consultants regarding the proposed research. Include key outcomes, action items and recommendations. If available, provide a copy of the communication from the FDA indicating the IND or IDE application is active/safe to proceed.
- If the clinical trial will be conducted at international sites, provide equivalent information and supporting documentation relevant to the product indication/label and regulatory approval and/or filings in the host country(ies).

- **Attachment 11: Study Personnel and Organization (no page limit): Start each document on a new page. Combine into one document and upload as "Personnel. pdf". *(Attachment 11 is applicable and required for all applications/proposals submitted under the MMRDA-CRCTO.)*** The Study Personnel and Organization attachment should include the components listed below.
  - **Organizational Chart:** Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers and/or departments and name each person's position on the project. Include any separate laboratory or testing centers. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, as appropriate, including the location of the organization. If applicable, identify the Regulatory Agency sponsor and any external consultants or other experts who will assist with Regulatory Agency sponsor applications. While there is no specified format for this information, a table(s) or diagram is recommended.
  - **Study Personnel Description:** Describe the composition of the study team in enough detail to determine whether the team includes relevant subject matter expertise to accomplish the proposed work. Include the roles of the individuals named in the organizational chart along with any external consultants or advisors who will provide critical guidance and input to the study team (e.g., independent research monitor, statistician, regulatory expert, commercialization consultant, clinical ethicist, patient advocate). Study coordinator(s) should be included. Describe how the levels of effort for each individual are appropriate to successfully support the proposed research.
  - **Study Management Plan:** Describe the day-to-day management of the proposed clinical trial. Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical trial involves more than one institution, clearly describe the multi-institutional structure governing the

research protocol(s) across all participating institutions. If applicable, describe how communication and data transfer between/among the collaborating institutions will occur, as well as how data, specimens and/or imaging products obtained during the study will be handled and shared. Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 12: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants/offerors must complete and submit the Required Representations document available on eBRAP. For more information, see the General Submission Instructions, Appendix 8, Section B.
- **Attachment 13: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP. Refer to the General Submission Instructions, Section V.B.(c), for instructions and considerations.

(c) Additional Application/Proposal Materials:

The following are additional forms for application/proposal submission. For detailed instructions for Grants.gov submissions, refer to the General Submission Instructions, Section IV.C.; and for eBRAP submissions, refer to the General Submission Instructions, Section V.B.

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants/offerors must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application/Proposal Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications/proposals recommended for funding.

If the resultant award is a contract that exceeds $900,000 and the offeror is other than a small business, the contractor will be required to submit a subcontracting plan for small business concerns, in accordance with FAR 19.7. A mutually agreeable plan will be developed during the award negotiation process and incorporated as part of the resultant contract.

5. Submission Requirements

5.1. Location of Application/Proposal Package

Download the application/proposal package components for HT942526JWMRPMMRDA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant/offeror organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application/proposal through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications/proposals to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application/proposal under consideration. More information regarding SAM registration can be found in the General Submission Instructions, Section IV.A.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application/proposal submissions. The workflow below shows which portal system to use for pre- and full application/proposal submissions, respectively.



5.3.1. Preapplication/Preproposal Submission

All preapplication/preproposal components must be submitted by the PI through eBRAP. Refer to the General Submission Instructions, Section III, for considerations and detailed instructions regarding preapplication/preproposal submission.

During the preapplication/preproposal process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application/proposal submission process. The eBRAP log number, application/proposal title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire application/proposal submission process. Inconsistencies may delay application/proposal processing and limit or negate the ability to view, modify and verify the application/proposal in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

When starting the preapplication/preproposal, PIs should select a Mechanism Option appropriate to their preapplication/preproposal:

If the Application/Proposal:	Select Mechanism Option:
DOES NOT INCLUDE human subjects, identifiable human biological specimens, or collection/use of raw/source human data (e.g., not deidentified)	Military Medical Research and Development Award (MMRDA)
INCLUDES any human subjects, identifiable human biological specimens, or collection/use of raw/source human data (e.g., not deidentified)	Military Medical Research and Development Award – Clinical Research or Clinical Trial Option (MMRDA-CRCTO)

5.3.2. Full Application/Proposal Submission

Grants.gov Submissions: Full applications/proposals from extramural organizations *must* be submitted through the Grants.gov Workspace. Refer to the General Submission Instructions, Section IV, for considerations and detailed instructions regarding Grants.gov submissions.

eBRAP Submissions: Only intramural DOW organizations may submit full applications/ proposals through eBRAP. Refer to the General Submission Instructions, Section V, for considerations and detailed instructions regarding eBRAP submissions.

5.3.3. Applicant/Offeror Verification of Full Application/Proposal Submission in eBRAP

Independent of the submission portal, once the full application/proposal is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application/proposal submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application/proposal submission deadline.*** Other application/proposal components, including subaward budget(s) and subaward budget justification(s), may be changed until the application/proposal verification period ends. The full application/proposal cannot be modified once the verification period ends.

5.4. Submission Dates and Times

The preapplication/preproposal and full application/proposal submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application/proposal components must be submitted by the deadlines stipulated in this BAA. There are no grace periods for deadlines; failure to meet submission deadlines will result in

application/proposal rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant/offeror.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Review Information

6.1. Application/Proposal Compliance Review

Submitting applications/proposals that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s)/proposal(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application/proposal and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application/proposal withdrawal. Refer to the General Submission Instructions, Appendix 7, Section C.

Members of the FY26 JWMRP Programmatic Panel must not be involved in any preapplication/preproposal or full application/proposal including, but not limited to, concept design, application/proposal development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 JWMRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Preapplication/Preproposal Screening Criteria

To determine the merits of the preapplication/preproposal and the relevance to the mission of the JWMRP, preapplications/preproposals will be screened based on the following criteria:

- Whether the preapplication/preproposal describes the continuation of a prior year effort that is ongoing/active at the time of preapplication/preproposal submission or that was completed no more than two years prior to the preapplication/preproposal submission deadline.
- Whether the preapplication/preproposal describes the continuation of a prior year effort that achieved a TRL/KRL of 5 or greater.
- Whether the PI for the proposed follow-on effort is the same as the PI of the prior year effort described in the preapplication/preproposal.
- How well the preapplication/preproposal describes a follow-on effort that is a logical continuation of a previously funded, prior year materiel/knowledge product research and development effort, while avoiding interdependency of aims.
- How well the proposed effort addresses at least one of the FY26 JWMRP Focus Areas.

- Relative potential of the proposed effort to augment and/or accelerate clinical, technical or materiel/knowledge product development with a clear benefit to military medicine.
- How well the preapplication/preproposal adequately describes the products or deliverables expected from the proposed follow-on effort and any associated challenges.
- How well the regulatory strategy, commercialization strategy and the estimated TRL/KRL demonstrates the transition potential of the anticipated product/outcome.

6.2.2. Peer Review Criteria

To determine technical merit, all applications/proposals will be evaluated individually according to the following **scored criteria**, of which **Research Strategy and Feasibility** and **Impact** are equally of most importance, with the remaining criteria listed in decreasing order of importance:

- **Research Strategy and Feasibility**
  - How well the application/proposal presents the scientific rationale behind the proposed research or materiel/knowledge product development effort, including relevant literature citations, preliminary data, and/or preclinical data, to support feasibility.
  - How well the application/proposal states the hypotheses and/or the objective(s) of the study.
  - How well the application/proposal describes the experimental design, methods, analyses, choice of study model, and endpoints/outcome measures, in sufficient detail for evaluation of feasibility and effectiveness in supporting the completion of the project aims.
  - How well the study is designed to achieve reproducible and rigorous results, including, as applicable, controls, sample size estimation, blinding, randomization and data handling.
  - Whether the SOW indicates a feasible plan and timeline to conduct the research, and how well it provides clearly defined milestones.
  - How well the application/proposal describes potential problem areas, including interdependency of aims (i.e., dependency on successful outcomes of other ongoing related research efforts), and discusses a strategy with alternative methods/approaches for overcoming obstacles.
  - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.
- **Additional Research Strategy and Feasibility Review Criteria for Applications/Proposals Submitted Under the MMRDA-CRCTO**
  - Whether the application/proposal clearly describes an observational or experimental study.
  - Whether the proposed clinical study/trial methodology and study variables are described in sufficient detail to demonstrate a clear course of action and justification for the study.
  - To what degree the outcomes address current clinical needs and how they compare with currently available standards of care.

- Whether the proposal contains an adequate and feasible description of study observations/interventions, evaluations and follow-up procedures (including any data or sample collection).
- Whether the proposal contains an adequate description of data collection and handling, including rules for stopping data collection, how outliers will be defined and handled, and identification of primary endpoints/outcomes.

- **Impact**
  - The degree to which the proposed effort is relevant to the role of the JWMRP in addressing high-priority DOW medical requirements and capability gaps and accelerating the development of products that will impact the Warfighter within the context of the FY26 JWMRP Focus Area(s) addressed by the application/proposal.
  - To what degree the knowledge, technologies, or products gained from the research will benefit military Service Members, with the potential to benefit military Family beneficiaries, Veterans and the American public.
  - To what degree the research will result in improvement over currently available military health care standards and practices.
  - To what degree the anticipated short-term outcomes(s)/products(s) (knowledge and/or materiel) of the proposed effort will impact the relevant populations.
  - To what degree the proposed effort will augment and/or accelerate product development (as applicable).
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Transition Plan**
  - Whether the transition plan is appropriate and well-described.
  - Whether the proposed research meets a current TRL or KRL of 5 or higher, and whether the proposed target TRL or KRL is realistic and appropriate.
  - Whether the timeline and milestones for transitioning the anticipated research outcomes to the next phase of development (i.e., next-phase clinical trials, commercialization/ transition to industry, delivery to market, incorporation into clinical practice, and/or approval by the FDA) are achievable.
  - Whether the steps for adapting and transitioning a civilian knowledge/product/ intervention for military fielding/adoption/use are reasonable and achievable.
  - To what degree the collaborations and other resources (e.g., DOW partners, clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees, training providers/resources) intended to help advance the research outcome(s) are established and/or achievable.
  - Whether the funding strategy to transition the research outcome(s) to the next level of investigation, development, and/or commercialization is reasonable and achievable.
  - How well the application/proposal identifies intellectual property ownership rights and/or demonstrates the appropriate access to the intellectual property necessary for the development and/or commercialization of products or technologies supported by this funding opportunity announcement and identifies the government's ability to access such products or technologies in the future.

- How well the application/proposal describes an appropriate Intellectual and Material Property Plan for resolving intellectual and material property issues among participating organizations, (if applicable).
- How well the application/proposal describes any active SBIR/STTR data rights (if applicable).
- Whether the risk analysis for cost, schedule, manufacturability and sustainability is realistic and reasonable (if applicable).

- **Regulatory Strategy (*for applications/proposals submitted under the MMRDA-CRCTO)***
  - Whether the application/proposal includes documentation that the study is exempt from regulatory agency oversight, or that the IND or IDE application (and/or international equivalent) has been submitted to the Regulatory Agency, as appropriate.
  - How well the submission documentation provided supports the feasibility of acquiring an active IND approval or IDE (and/or international equivalent) covering the proposed study/trial, if applicable.
  - To what extent the regulatory strategy and product development plan is well-described and appropriate to support the product label indication or product label change, if applicable.
  - Whether the types of meetings the research team had with regulatory agencies or consultants regarding the proposed research and the submission filing strategy are appropriate, including any implications of conducting studies/trials at international sites.
- **Study Population Recruitment/Sample Acquisition and Safety Plan *(for applications/proposals submitted under the MMRDA-CRCTO)***
  - To what degree the study/sample population, number of study participants/samples, criteria for inclusion/exclusion, and the methods for recruitment/accrual of study participants, samples, and/or data sets are reasonable to meet the needs of the proposed research.
  - Whether the application/proposal demonstrates that the research team has access to the proposed study/sample population at each site and describes the efforts that will be made to achieve accrual goals.
  - Whether the projected enrollment estimate from the target population is feasible and includes measures to minimize bias.
  - How well the application/proposal addresses any potential barriers to study participant/ sample accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment and/or poor retention, for example.
  - As applicable, to what degree the process for seeking informed consent is appropriate, and whether safeguards are in place for vulnerable populations.
  - As applicable, how the level of risk to study participants is minimized and how the safety monitoring and reporting plan is appropriate for the level of risk.
  - Whether the distribution of the proposed enrollment on the basis of age, sex, race, and/or ethnicity is appropriate for the proposed research, and if applicable, whether there is strong justification for limiting inclusion of any demographic group.
  - Whether the strategy for the inclusion of women and minorities is appropriate for the proposed research. Studies utilizing human biospecimens or datasets that cannot be

linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.

- **Data and Statistical Analysis Plan**
  - To what degree the statistical model and data analysis plan are suitable for the planned study objectives.
  - To what degree the statistical plan, including power analysis for sample size projections, is appropriate to meet the objectives of the study.
- **Personnel**
  - To what degree the background and expertise of the PI and other key personnel demonstrate their ability to accomplish the proposed work, including whether there is evidence of sufficient clinical and/or statistical expertise (as applicable).
  - To what degree the levels of effort of the PI and other key personnel are appropriate for successful support of the proposed research.

In addition, the following criteria will also contribute to the overall evaluation of the application/proposal, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
- **Application/Proposal Presentation**
  - To what extent the writing, clarity and presentation of the submission components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s)/proposal(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 JWMRP, as evidenced by the following:
  - Military relevance, including alignment with and balance within and across the identified DOW and services medical research priorities and portfolios

- Relative potential to augment and/or accelerate clinical, technical or materiel/knowledge product development efforts that directly benefit military medicine
- Relative transition potential of the anticipated product/outcome
- Relative impact on Service Members, their Families and Veterans

6.3. Application/proposal Review and Selection Process

6.3.1. Preapplication/Preproposal

Following the preapplication/preproposal screening, PIs will be notified as to whether they are invited to submit full applications/proposals. The estimated date when PIs can expect to receive notification of an invitation to submit a full application/proposal is indicated in Section 1, Basic Information about the Funding Opportunity. No feedback (e.g., a critique of the preapplication/preproposal's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application/proposal is based on the contents of the preapplication/preproposal, investigators should not change the title or research objectives after the preapplication/preproposal is submitted.

6.3.2. Full Application/Proposal

All applications/proposals are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications/proposals against established criteria to determine technical merit, where each application/proposal is assessed for its own merit, independent of other applications/proposals. The second tier is **programmatic review**, a comparison-based process in which applications/proposals with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications/proposals from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications/proposals received is contingent upon the availability of federal funds for this program, the number of applications/proposals received, the quality and merit of the applications/proposals as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

The risk posed by an applicant/offeror will be assessed prior to award, including but not limited to financial stability and history of performance.

An award may not be made if it is determined by the DHACA Warranted Official that COIs cannot be adequately mitigated.

Prior to making an award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant/offeror that is available in the SAM.

An applicant/offeror organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant/offeror, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant/offeror's integrity, business ethics and record of performance under federal awards when determining an awardee's qualification prior to award, according to the qualification standards of DoDGARs, Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant/offeror organizations must disclose foreign affiliations of all key personnel named on applications/proposals. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications/proposals. Applicant/offeror organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application/proposal received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application/proposal and an information paper describing the application/proposal receipt and review process for the JWMRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application/proposal is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the awardee organization.

Only an appointed DHACA Warranted Official may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the DHACA Warranted Official is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

For assistance agreement awards, an organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

For contract awards and OTs, an organization may request and negotiate pre-contract/pre-agreement costs prior to award.

Refer to the General Submission Instructions, Section I.D, Pre-Award Costs section, for additional information about pre-award costs.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this BAA.

Applicable requirements in the FAR, found in 48 CFR, Chapter 1; and Defense Federal Acquisition Regulation Supplement (DFARS), found in 48 CFR, Chapter 2, apply to contracts resulting from this BAA.

Refer to the General Submission Instructions, Appendix 7, for general information regarding administrative requirements.

Refer to the General Submission Instructions, Appendix 8, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant/offeror organization, DHACA will not issue any new awards to the applicant/offeror organization until all delinquent reports have been submitted.

Applications/proposals recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review. Refer to the General Submission Instructions, Appendix 6, for additional information.

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on ClinicalTrials.gov.

8.2. Reporting

Annual technical progress reports, annual quad charts, and a final technical progress report will be required for all applications recommended for funding. Quarterly reports will also be required for funded applications proposing a clinical trial. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

If the award made under this funding opportunity is a contract or OT, additional reporting requirements may apply.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

PHS Inclusion Enrollment Reporting ***(only required for clinical research studies and clinical trials)***: Enrollment reporting on the basis of sex, race, and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Awards resulting from this broad agency announcement may entail additional reporting requirements related to awardee integrity and performance matters. Awardee organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These awardees are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations within General Submission Instructions, Appendix 8, Section B.

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

Refer to the General Submission Instructions, Appendix 7, Section G, for general information on organization or PI changes.

9. Other Information

9.1. Broad Agency Announcement Version

Questions related to this broad agency announcement should refer to the program name, the broad agency announcement name and the broad agency announcement version code CD26_01Bd.

9.2. Administrative Actions

After receipt of preapplications/preproposals or full applications/proposals, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the preapplication/preproposal:

- Preapplication/preproposal is missing or incomplete.
- Preapplication/preproposal does not adhere to the provided template format.
- Preapplication/preproposal exceeds page limit.

The following will result in administrative rejection of the full application/proposal:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application/proposal for which a letter of invitation was not issued.

For applications/proposals submitted under the MMRDA-CRCTO and/or involving human subjects/samples/data:

- Attachment 9, Study Population Recruitment/Sample Acquisition and Safety Plan, is missing.
- Attachment 10, Regulatory Strategy, is missing.
- Attachment 11, Study Personnel and Organization is missing

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application/proposal:

- A member of the FY26 JWMRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the preapplication/preproposal or full application/proposal processes.

- The application/proposal includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant/offeror or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application/proposal from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government applicant/offeror organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application/proposal fails to conform to this broad agency announcement description.
- The application/proposal includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application/proposal includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The PI does not meet the eligibility criteria.
- The invited application/proposal proposes a different research project than that described in the preapplication/preproposal.
- The invited application/proposal proposes research that is not a logical continuation of the previously DOW-funded research or development effort identified in the notification of invitation.

For applications/proposals involving animal research:

- Attachment 8, Animal Research Plan, is missing.

9.2.4. Withhold

Applications/proposals that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Warranted Official for a determination of the final disposition of the application/proposal.

Appendix 1. Full Application/Proposal Submission Checklist

Full Application/Proposal Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Impact Statement and Military Relevance Statement – Attachment 6, upload as "Impact.pdf"	☐
Post-Award Transition Plan – Attachment 7, upload as "Transition.pdf"	☐
Animal Research Plan *(if applicable)* – Attachment 8, upload as "AnimalResPlan.pdf"	☐
Study Population Recruitment/Sample Acquisition and Safety Plan *(if applicable)* – Attachment 9, upload as "HumSubProc.pdf"	☐
Regulatory Strategy *(if applicable)* – Attachment 10, upload as "Regulatory.pdf"	☐
Study Personnel and Organization *(if applicable)* – Attachment 11, upload as "Personnel.pdf"	☐
Representations *(Grants.gov submissions only)* – Attachment 12, upload as "RequiredReps.pdf"	☐
Suggested Intragovernmental/Intramural Budget Form *(if applicable)* – Attachment 13, upload as "IGBudget.pdf"	☐
Additional Application/Proposal Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) *(if applicable)*	☐

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting In Vivo Experiments
BAA	Broad Agency Announcement
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
COI	Conflict of Interest
CONSORT	Consolidated Standards of Reporting Trials
DFARS	Defense Federal Acquisition Regulation Supplement
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDI	Department of Defense Instruction
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FAR	Federal Acquisition Regulation
FDA	U.S. Food and Drug Administration
FFRDC	Federally Funded Research and Development Center
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IPR	In-Progress Review
IRB	Institutional Review Board
JWMRP	Joint Warfighter Medical Research Program
KRL	Knowledge Readiness Level
M	Million
MIPR	Military Interdepartmental Purchase Request
MMRDA	Military Medical Research and Development Award
MMRDA-CRCTO	Military Medical Research and Development Award – Clinical Research or Clinical Trial Option
MSKI	Musculoskeletal Injuries

ORRC	Office of Research and Regulatory Compliance
OTs	Other Transactions
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SBIR	Small Business Innovation Research
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
STTR	Small Business Technology Transfer
TRL	Technology Readiness Level
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs

Appendix 3. Technology Readiness Levels and Knowledge Readiness Levels

TRLs: TRLs are used to categorize the product maturity of materiel solutions. The DOW uses Technology Readiness Assessment (TRA) for systematic assessment of technical maturity of relevant materiel solutions across all acquisition domains. Biomedical TRL definitions and descriptions have been developed that account for regulatory context for technology maturity and *intended context of use*. The FY26 JWMRP uses the Veterans Affairs Biomedical Technology Readiness Levels: https://www.research.va.gov/programs/tech_transfer/Biomedical-TRL-Guideline-Sheets.pdf.

KRLs: The scientific maturity of knowledge products resulting from biomedical research is not assessed in the same manner as that of materiel solutions. At the request of the DHA R&D MRDC, the Rand Corporation developed and released a framework to assess the relative scientific maturity of knowledge products. This process is described in a 2019 Rand Corporation report (https://www.rand.org/pubs/research_reports/RR2127.html). The following table of KRLs may be used when determining KRL level.